MagGenix

Transforming Cell Therapeutics Through Magnetic Precision

MagGenix is developing A patent-Pending
magnetogenetic platform Enabling
Cell Therapy Where & When Needed

Check it out

Cell Therapies of Tomorrow …

are Not very Futuristic

3/4

Induced Cytokine Release Syndrome

2/5

Induced Neurotoxicity

1/2

Hospitalized in the ICU

Why do we dilute cell therapies across the body?

Why is organ damage so common with CAR-T?

Why does cell therapy manufacturing take so long?

Current cell therapies, like CAR-T, only effectively treat the 10% of cancers that are liquid.

What about the other 90%: solid-tumor cancers?

The MagGenix Platform

TRUE
BIO + TECH

Using our patent-pending technology, we can interact with our biology the same way our phones interact with the internet: over-the-air electromagnetic waves. Our technology connects the electronics and biological worlds to offer unlimited potential in an increasingly bio- and tech-driven society.

We control cells using electromagnets

Unparalleled Spatiotemporal Resolution

PRECISE THERAPY

Our platform grants the ability for precise cellular activation in both location and timeframe. This resolution allows for the system to be used inside humans Confining + Concentrating cell therapies only where needed, reducing off-target effects while boosting efficacy.

TOOLSETS FOR ALL OF TODAY’S THERAPIES

Our proprietary gene circuity implements across species, existing therapeutics, and transfection processes to give electromagnetic control to any biological system.

Implementation into autologous/allogeneic, viral/non-viral, and human/murine cell therapeutics

People

Joshua Devier

CEO

Interested in the clinical translation of synthetic biology, Joshua has experience pursuing academic and entrepreneurial research interlacing the biological and computational worlds. Joshua is an MD/PhD student at UCSF/UC Berkeley, and, with past engineering leadership experience, hopes to advance the clinical SynBio space utilizing MagGenix’s next-gen cellular engineering platform.

Maya Zhang

CFO

Having worked in multiple labs focusing on nociception, antibody production, and cancer immunotherapies, Maya is a Georgia Tech PhD student with experience working with both the peripheral nervous system and the adaptive immune system alike.

Joshua Zhou

CIO

With past experience in the Bukowski Group and Hopkins iGEM, Joshua is a University of Chicago PhD student with experience creating simulations and models ranging from quantum chemical density functional theory (DFT) techniques to simple macroscopic balances. He additionally has familiarity with synthetic biology as well as analyzing micro-structured materials.